Summary 4, 6-0-Benzylidene-D-glucopyranose (BG), a derivative of benzaldehyde (BA), whose anti-tumour action has often been reported, showed responses in 10 out of 24 patients (41.7%). These patients consisted of 11 cases of primary lung cancer, 4 of metastatic lung cancer, 5 of gastric cancer, and one each of cancer of the sigmoid colon, liver, pancreas and prostate. There were two complete responses (one each of ipsilateral lung metastasis from breast cancer and metastatic liver lesions due to gastric cancer). The mean total dose of BG was 392.6 g, given by intravenous infusion of 1.2 g BG in 100 ml saline twice daily. The treatment was discontinued when no response was observed after two months. Careful monitoring showed no toxic action of BG at these large doses. Complete necrotic liquefaction of tumour, without any damage to surrounding tissue, was seen in 2 of 3 cases in which histological examination was feasible. It is apparent that BG, like BA, is not a cytotoxic agent in the ordinary sense, but its mechanism of action is still unknown.
The anti-tumour effects of various aldehydes have often been reported (Osato, 1950; Conroy et al., 1975; Sessa et al., 1977; Derin et al., 1978; Egyud & Gyorgyi, 1968) . Among them, the effects of benzaldehyde (BA), originally extracted from fig fruit, on experimentally induced carcinomas (Takeuchi et al., 1978; Petterson et al., 1985; Soga et al., 1985) , on cultured cell lines (Zundel et al., 1975; Miyakawa et al., 1979; Watanuki & Sakaguchi, 1980; Watanuki & Sakaguchi, 1981; Isida et al., 1983; Nambata et al., 1982; Petterson et al., 1983; Petterson et al., 1983; Petterson et al., 1985) and on advanced stage human carcinomas (Kochi et al., 1980; Kochi et al., 1985) have attracted considerable attention. Inhibition of experimental and spontaneous pulmonary metastasis in C3H/He mice with CRT ( + ) cells, and dose-dependent mode of this inhibition have been reported by colleagues in other departments. (Ochiai et al., 1986; Masuyama et al., 1987) . Figure I shows the molecular structure of 4, 6-0-Benzylidene-D-glucopyranose (BG), a glucoside derivative of BA. BG is soluble enough in saline to be injected intravenously, unlike BA which has to be taken orally by the patients in the form of P-cyclo-dextrin inclusion compound.
One remarkable feature common to BA and BG is the lack of toxicity, either acute or chronic. According to the past tests (Kaken in-house report, 1986) , the LD% of BG in mice and rats is more than 400 mg kg-' by intravenous injection, more than 3,000 mg kg-' by oral, and more than 1,440 mg kg-by peritoneal administration. No (Kochi et al., 1985) , including anti-tumour response in 55.3% of 65 patients, with 10.7% complete regression. The aim of the present study was to confirm the clinical efficacy of BG on various types of solid malignant carcinomas, as an extended Phase I study.
Patients and methods
A total of 24 patients with advanced stage carcinomas were included in the present trial. The diagnoses of all cases were confirmed by histological assessment from operation or biopsy. They consisted of I I cases of primary lung cancer, 4 with metastatic lung cancer, 5 patients with gastric cancer, and one patient each with cancer of the sigmoid colon, liver, pancreas and prostate. The characteristics of the 20 male and 4 female cases are summarised in Table I . The average age of this group was 63.6 years, ranging from 11 to 86-years-old. The performance status of the patients was evaluated before and after the treatment.
BG was a gift from Kaken Pharmaceutical Co, (Tokyo, Japan), in vials each containing 1.2 g lyophilised BG (98% 4,6-0-benzylidene glucopyranose). Doses of 1.2 g BG dissolved in 100 ml saline (pH 4.5-6.5) were infused intravenously every morning and evening during the treatment period. This dose, suggested by the manufacturer's research group, was regarded as being considerably within the safety limit, in view of the virtual lack of any toxicity suggested by animal tests, but signs of any side effects were carefully 4, 6-0-BENZYLIDENE-D-GLUCOPYRANOSE 437 and lung metastases due to breast cancer, and a patient with metastatic liver lesions due to gastric cancer. A partial response (PR) was noted in 8 of the 24 patients, while MR was seen in 4 patients, yielding an overall response rate of 58.3%. An anti-tumour response rate of 41.6% is obtained if only CR and PR are considered. Ten of the 24 patients showed no response (NC) to therapy, or had progressive disease (Table  II) . At the start of treatment, the majority (18 of 24) of the patients had a performance status of grade 2 or worse. As shown in Table III , marked improvement of performance status was noted in patients who showed an objective therapeutic response (CR and PR), and improvement in performance status was also noted among those patients with MR or NC response. The mean survival time of the total cases at completion of the trial was 10.3 months. The 2 patients who had a CR anti-tumour response are still alive 11 and 20 months after the treatment (Figures 2 and 3) .
Therapeutic assessment by histologic study was possible in three of the 24 cases, apart from appraisal of the size of the tumours by clinical methods. Of these three cases, two were evaluated by postmortem studies, and one was studied by examination of surgical specimens obtained through operation following BG treatment. Characteristic tissue response to BG, i.e., massive necrosis of the tumour tissue, was found but no apparent damage was found in the surrounding normal tissue.
No haematological, liver, renal or cardiac toxicity was attributable to treatment, and no nausea, vomiting or other adverse reactions were noted.
Discussion
Among 24 patients response was seen in 10, with 2 CR. These results were comparable to those of Kochi et al. (1985) , and support the view that BG can be clinically useful for the treatment of tumours. One of the interesting features revealed in this study is the apparent lack of accompanying toxicity of BG, at least with the size of dose used, which is exceptional for anti-tumour agents and widens the future potential use of this drug. Another is the specific necrotic liquefaction of the tumour cells by this treatment, without any damage to surrounding normal cells seen in two cases in which histological assessment was feasible. This feature, which might have also been present in the other cases, may be a characterisitc of BG. Watanuki et al. (1980 Watanuki et al. ( , 1981 noted that benzaldehyde selectively inhibited the uptake of nutrients into SV-40 transformed cell lines, but not their normal counterparts. These findings were also confirmed by other investigators (Takeuchi et al., 1978; Ishida et al., 1983) . The mechanism of the anti-tumour action of BG is still unclear, except that it might 
